Therapeutic potential of iron chelators in diseases associated with iron mismanagement (Q36461028)

14 August 2017

1 reference

title

Therapeutic potential of iron chelators in diseases associated with iron mismanagement (English)

1 reference

14 August 2017

Eugene D Weinberg

1

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Journal of Pharmacy and Pharmacology

14 August 2017

published in

1 reference

14 August 2017

volume

58

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

575-584

1 reference

Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Gallium nitrate for the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part II. caffeic, chlorogenic and rosmarinic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

In vitro inhibition of human cytomegalovirus replication by desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

New developments in iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The biology of transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Role of deferiprone in chelation therapy for transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida. Impact on the development of buccal preparations of lactoferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Synthesis of feralex a novel aluminum/iron chelating compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Effects of artemisinin-tagged holotransferrin on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Differential inhibition of inducible T cell cytokine secretion by potent iron chelators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron chelation, angiogenesis and tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Design of clinically useful iron(III)-selective chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Intramuscular desferrioxamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron chelation therapy for malaria: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Gallium disrupts iron metabolism of mycobacteria residing within human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Monitoring and treatment of iron overload: state of the art and new approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Effects of chloroquine on viral infections: an old drug against today's diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

An Iron-binding Component in Human Blood Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Enhancement of classic Kaposi's sarcoma growth after intralesional injections of desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Constitutive expression of human lactoferrin and its N-lobe in rice plants to confer disease resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron chelator research: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Safety determination for the use of bovine milk-derived lactoferrin as a component of an antimicrobial beef carcass spray

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Development of a pharmaceutical apotransferrin product for iron binding therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron withholding: a defense against viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The role of iron in protozoan and fungal infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Modulation of intramacrophage iron metabolism during microbial cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Human lactoferrin: a novel therapeutic with broad spectrum potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Prevention of anthracycline cardiotoxicity by iron chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

The inhibitory activity of serum to prevent bacterial adhesion is mainly due to apo-transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Suppression of bacterial biofilm formation by iron limitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

Bacterial lactoferrin-binding protein A binds to both domains of the human lactoferrin C-lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.58.5.0001

21 January 2018

Identifiers

DOI

10.1211/JPP.58.5.0001

1 reference

14 August 2017

1 reference